»ùÒò×é±à¼¼¼ÊõÔÚ¸Éϸ°û¼²²¡Ä£Ðͽ¨Á¢ºÍ¾«×¼Ò½ÁÆÖеÄÓ¦ÓÃ
ÉúÎïͨ¡°ºËÐÄ¿¯ÎÀ¸Ä¿´´°ìÓÚ2002Ä꣬Ö÷Ö¼ÔÚÓÚÏò¹úÄÚרҵÈËʿչʾ¿ÆÑкËÐÄ¿¯ÎÒÔ¼°ÉúÃü¿ÆÑ§ÁìÓòÔÓ־ÿÆÚÖØµãÄÚÈÝ£¬Îª¶ÁÕß³ÊÏÖ¾«²Ê·×³ÊµÄ¹úÄÚ¿ÆÑж¯Ïò£¬ºÍÖØ´ó¿ÆÑнøÕ¹¡£Ä¿Ç°°üÀ¨¡¶ÒÅ´«¡·¡¢¡¶ÖйúÉúÎ﹤³ÌÔÓÖ¾¡·¡¢¡¶¿ÆÑ§Í¨±¨¡·µÈÖØµãÆÚ¿¯£¬Ò²»¶ÓÉúÎïÀàÆÚ¿¯ÁªÏµºÏ×÷£¨ÁªÏµÓÊÏ䣺[email protected]£©¡£
¾«×¼Ò½ÁÆÇ¿µ÷Õë¶Ô²»Í¬¸öÌ嶍֯¸öÐÔ»¯ÖÎÁÆ·½°¸,ÆäÍÆÐÐÐèÒª¾«×¼¼²²¡Ä£Ð͵Ľ¨Á¢¡£ÈËÀà¸Éϸ°ûÒòÆä¾ßÓжàÄÜÐÔ¶ø³ÉΪÌåÍⲻͬÀàÐ͵ijÉÌåϸ°ûºÍÆ÷¹ÙСÌåµÄDZÔÚÀ´Ô´,ÆäÇ¿ÔöÖ³ÄÜÁ¦±£Ö¤Á˳ä×ãÔ²ÄÁÏÓÃÓÚ¿ÆÑзÖÎöºÍ´ó¹æÄ£Ò©Îïɸѡ¡£»ùÒò×é±à¼¼¼Êõ(ÓÈÆäÊÇCRISpR/Cas9¼¼Êõ)µÄ¿ìËÙ·¢Õ¹Ê¹µÃÔÚÈ˶àÄܸÉϸ°ûºÍ³ÉÌå¸Éϸ°ûÖнøÐиßЧ»ùÒò×é±à¼³ÉΪ¿ÉÄÜ¡£Á½ÕßµÄÓÐЧ½áºÏÄܽ¨Á¢ÆðÕë¶Ô²»Í¬ÒÅ´«Ö²¡±³¾°µÄ¡°¸öÐÔ»¯¡±¼²²¡Ä£ÐÍ,ÓÐÀûÓÚÉîÈë½âÎö²»Í¬ÒÅ´«Í»±äµÄÖ²¡»úÖÆºÍ¿ª·¢¸ßÕë¶ÔÐԵľ«×¼Ò½ÁÆ·½°¸¡£Öйú¿ÆÑ§ÔºÉϺ£ÉúÃü¿ÆÑ§Ñо¿ÔºÓªÑø¿ÆÑ§Ñо¿ËùµÄÑо¿ÈËÔ±¶Ô»ùÒò×é±à¼¼¼ÊõÔÚÈËÀà¸Éϸ°ûÖеÄÓ¦ÓÃÒÔ¼°ÀûÓøÉϸ°û¼²²¡Ä£ÐÍÄ£Ä⺱¼û²¡ºÍÖ×Áö·¢ÉúµÄÑо¿½øÐÐÁË×ÛÊö¡£
2015Äê³õËæ×ÅÃÀ¹ú×Üͳ°Â°ÍÂíÐû²¼¿ªÕ¹ÊµÊ©¾«×¼Ò½ÁƼƻ®(precision medicine initiative)£¬¾«×¼Ò½ÁÆÁ¢¿ÌÒýÆð¹úÄÚÍâ¸÷½çµÄ¸ß¶È¹Ø×¢£¬Æä»ù±¾¸ÅÄîÊǸù¾Ý¸öÌ岻ͬÒÅ´«±³¾°ºÍ½¡¿µ×´Ì¬Öƶ¨¸öÌ廯µÄ¼²²¡Ô¤·ÀºÍÖÎÁÆ·½°¸¡£¾«×¼Ò½ÁƵÄʵÏÖÐèÒª´ó¹æÄ£»ùÒò×é²âÐòÖ§³Ö£¬Í¬Ê±Ò²ÐèÒªÓÐЧµÄʵÑéºÍÒ©Îïɸѡƽ̨µÄ½¨Á¢£¬ºóÕß½«ÓÐÖúÓÚ¶ÔÒÅ´«²âÐòÊý¾ÝµÄÉîÈë½âÎö£¬ºÍÕë¶Ô²»Í¬Ö²¡ÒÅ´«±³¾°µÄ¸öÐÔ»¯ÖÎÁÆ·½°¸Ñз¢¡£
»ùÒò×é±à¼¼¼Êõ(Genome editing technology) ½áºÏÈ˶àÄܸÉϸ°û(Human pluripotent stem cells, hpSCs)ÒÔ¼°³ÉÌå¸Éϸ°ûÉúÎïѧ£¬ÌṩÁËÒ»¸ö¶ÀÌØµÄʵÑéÆ½Ì¨Ìåϵ£¬¿ÉÓÃÓÚ½¨Á¢¡°¸öÐÔ»¯¡±¼²²¡Ä£Ð͹©ÒÅ´«Í»±ä·ÖÎöºÍ´ó¹æÄ£Ò©Îïɸѡ¡£Ä¿Ç°£¬³£ÓõĻùÒò×é±à¼¼¼ÊõÖ÷Òª°üÀ¨Ð¿Ö¸ºËËáø(Zinc finger nucleases, ZFNs)¡¢Ààת¼¼¤»îÒò×ÓЧӦÎïºËËáø(Transcription activator-like effector nucleases, TALENs)ºÍ³É´Ø¹æÂɼä¸ô¶Ì»ØÎÄÖØ¸´ÐòÁÐϵͳ(Clustered regularly interspaced short palindromic repeats/CRISpR-associated proteins, CRISpR/Cas)¡£Ïà±ÈZFNºÍTALEN£¬CRISpR¼¼ÊõÓÉÓÚÔØÌå¹¹½¨¼òµ¥¡¢°ÐÏòλµãÑ¡ÔñÁé»î¡¢°ÐÏòЧÂʸü¸ß£¬±»¹ã·ºÓÃÓÚ¸÷Ààϸ°ûºÍģʽ¶¯ÎïµÄ»ùÒò×é±à¼¡£
ÔÚÄ£ÄâÈËÀ༲²¡·½Ã棬È˶àÄܸÉϸ°ûºÍ³ÉÌå¸Éϸ°ûÓÉÓÚ×ÔÉí¸Éϸ°ûÌØÐÔ¾ßÓÐһЩÃ÷ÏÔÓÅÊÆ£º(1)ÓµÓÐÈËÀà»ùÒò×飬½áºÏ»ùÒò×é±à¼¼¼Êõ£¬¿ÉÓÃÓÚ¾«È·Ä£ÄâÈËÀ༲²¡ÒÅ´«±³¾°£»(2)¾ßÓжàÄÜÐÔ£¬ÔÚÍâ½çºÏÊʵÄÓÕµ¼Ìõ¼þÏ£¬¿ÉÒÔ¶¨Ïò·Ö»¯Îª¸÷ÖÖÌåϸ°ûÀàÐͺÍÀàÆ÷¹ÙСÌå(Organoids)£¬²¢ÇÒÒ»¶¨³Ì¶ÈÉÏÌåÍâ·Ö»¯¹ý³ÌÄÜ·´Ó¦ÌåÄÚÕý³£·¢Óý¹ý³Ì£¬¿ÉÓÃÓڹ۲켲²¡·¢ÉúµÄÖмä״̬£»(3)¾ßÓÐÎÞÏÞÔöÖ³ºÍ×ÔÎÒ¸üÐÂÄÜÁ¦£¬Í¬Ê±Çø±ðÓÚ¸÷ÖÖת»¯Ï¸°ûϵ£¬¾ßÓÐÕý³£ºËÐÍ£¬ÌṩÁË´óÁ¿¸ü·ûºÏÉúÀí״̬µÄϸ°ûÓÃÓÚÑо¿ºÍÒ©Îïɸѡ¡£¡°¸öÐÔ»¯¡±¼²²¡Ä£Ð͵Ľ¨Á¢ÓÐÖúÓÚÉîÈë½âÎö²»Í¬ÒÅ´«Í»±äµÄÖ²¡»úÖÆºÍ¿ª·¢¸ßÕë¶ÔÐԵľ«×¼Ò½ÁÆ·½°¸¡£
ÕâÆªÎÄÕ¶ԻùÒò×é±à¼¼¼ÊõÔÚÈËÀà¸Éϸ°ûÖеÄÓ¦ÓÃÒÔ¼°ÀûÓøÉϸ°û¼²²¡Ä£ÐÍÄ£Ä⺱¼û²¡ºÍÖ×Áö·¢ÉúµÄÑо¿Õ¹¿ª×ÛÊö¡£ÎÄÕÂÖ¸³ö£¬¾«È·¼²²¡Ä£Ð͵Ľ¨Á¢ÔÚ¼²²¡»úÀí̽¾¿ºÍеÄÖÎÁÆ·½°¸¿ª·¢¹ý³ÌÖÐÖÁ¹ØÖØÒª¡£»ùÒò×é±à¼¼¼ÊõºÍ¶àÄܸÉϸ°û½áºÏ½¨Á¢µÄ¸Éϸ°û¼²²¡Ä£ÐÍ£¬Îª¼²²¡Ñо¿ÌṩÁËÒ»¸öȫеÄÑо¿Æ½Ì¨£¬ÄÜÔÚÈ˵ÄÌØ¶¨ÒÅ´«±³¾°ÏÂ(Ïà¶ÔСÊóµÈÆäËûģʽÉúÎï)£¬ÔÚ¸üÇкÏÉúÀí״̬µÄÕý³£Ï¸°ûÌåϵÖÐ(Ïà¶ÔÆäËû¸÷ÖÖת»¯Ï¸°ûϵ)£¬¸ü ¼Ó¾«È·µÄÔÙÏÖÈËÀ༲²¡µÄ·¢Éú¹ý³Ì¡£Ëæ×Ÿ÷ÖÖ¸Éϸ°ûÌåÍâ·Ö»¯Æ½Ì¨µÄ½¨Á¢ºÍ³ÉÊ죬ÌåÍâÅàÑøÌåϵµÄÓÅ»¯£¬»ùÒò×é±à¼¼¼ÊõµÄ½øÒ»²½·¢Õ¹£¬Õë¶Ô²»Í¬ÒÅ´«Ö²¡±³¾°µÄ¸Éϸ°û¡°¸öÐÔ»¯¡±¼²²¡Ä£Ðͽ«Îª¾«×¼Ò½ÁÆÌṩ¶ÀÌØµÄÑз¢Æ½Ì¨£¬ÖúÁ¦ÓÚеĸü¾ßÕë¶ÔÐÔµÄÒ©Î↑·¢¡£
ÔÎļìË÷£º
ΤÓà´ï, Àîˬ, Áõ¸Ä¸Ä, ÕÅÓÀÏÍ, ¶¡ÇïÈØ. »ùÒò×é±à¼¼¼ÊõÔÚ¸Éϸ°û¼²²¡Ä£Ðͽ¨Á¢ºÍ¾«×¼Ò½ÁÆÖеÄÓ¦ÓÃ[J]. ÒÅ´«, 2015, 37(10): 983-991.
Yuda Wei£¬ Shuang Li£¬ Gaigai Liu£¬ Yongxian Zhang£¬ Qiurong Ding. Use of genome editing tools in human stem cell-based disease modeling and precision medicine. HEREDITAS(Beijing), 2015, 37(10): 983-991.